LNSR News and Press, LENSAR Inc. From 07/24/23

Private equity-owned ophthalmology group, EyeSouth Partners, adopts ALLY for each operating room within its Gainesville, Georgia and Boynton Beach, Florida Ambulatory Surgery Centers (ASCs) Private equity-owned ophthalmology groups account for 14% of the U.S. based ASCs performing catarac...

2023-05-31 13:10:47 ET Gainers: Aridis Pharmaceuticals ( ARDS ) +130% . Marker Therapeutics MRKR +31% . SunCar Technology Group SDA +27% . T Stamp ( IDAI ) +25% . Inventiva ( IVA ) +19% . Eledon Pharmaceuticals ( ELDN ) +19% ...

2023-05-15 10:25:21 ET LENSAR, Inc. (LNSR) Q1 2023 Earnings Conference Call May 15, 2023, 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participant...

2023-05-15 07:18:12 ET LENSAR press release ( NASDAQ: LNSR ): Q1 GAAP EPS of -$0.40. Revenue of $8.25M (-11.7% Y/Y). For further details see: LENSAR GAAP EPS of -$0.40, revenue of $8.25M

Increased ALLY ® Adaptive Cataract Treatment System installed base to 19 systems with a backlog of additional 13 systems as of May 12, 2023 U.S. procedure volumes increased 13% over first quarter 2022; Procedure volumes increased >20% year-over-year at sites that have upgraded...

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s first quarter 2023 financial results will be ...

2023-03-16 09:33:06 ET LENSAR, Inc. (LNSR) Q4 2022 Earnings Call Transcript March 16, 2023 08:30 AM ET Company Participants Lee Roth - Burns McClellan Nick Curtis - Chief Executive Officer Tom Staab - Chief Financial Officer Conference Call Participants ...

2023-03-16 07:21:01 ET LENSAR press release ( NASDAQ: LNSR ): Q4 GAAP EPS of -$0.24 beats by $0.01 . Revenue of $10.2M (-9.1% Y/Y) beats by $0.2M . Earnings Before Interest, Taxes, Depreciation and Amortization  for the quarter ended December 31, 2022 was ...

Installed ten ALLY ® Adaptive Cataract Treatment Systems in 2022 with contracts for six additional ALLY Systems executed in December 2022; Installations expected in first half 2023 Positive surgeon feedback reinforces next generation speed, efficiency and economic benefits of ALL...

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2022 financial r...